



Courtesy by Bernard CHENEVIER - November - 2022




Courtesy by Alain WAGNER - November - 2022



Okayama University team welcomes Dr. A. Wagner from Strasbourg University
November 8th 2022

STRASBOURG INSTITUTE FOR DRUG DISCOVERY & DEVELOPMENT

**Innovation is *not just*
research !**



Sylviane Muller

Investment for Future Science (2010- ..)

Invest in few (9) Universities of to become Worldwide Class Players

University of Paris Saclay

University of Bordeaux

University of Aix Marseilles

Sorbonnes University

University of Paris Sciences et Lettres

Universtity of Paris Cité

University of Strasbourg

University of Nice Cote d'Azur

University of Grenoble Alpes

Strasbourg University & Drug Discovery

15 M€ / 10 years


High risk and translational research to treat cancer and inflammation

> 600 publications, 14 patents, 7 start-ups created

➤ **2011-2020 - LabEx Medalis**

➤ **2021-2028 - IMS aims to provide a dedicated site where all the expertise and skills required for drug development are combined, from student training, fundamental research, drug discovery to preclinical validation.**

Head: S. Muller



➤ **Medalis: 12 research teams (7 UMR), ≈200 people**

Medicinal chemistry,
chemoinformatics, biology,
immunology,
neurosciences, proteomics,
molecular imaging, ...



Sylviane Muller



Alexandre Detappe



Françoise Dantzer



Christopher Mueller



Frédéric Simonin



Dominique Bagnard



Pascal Villa



Sarah Cianféroni



Frédéric Bihel



Dominique Bonnet



Alain Wagner



Frédéric Boisson

Funding innovative projects in the field of drug development

→ Annual calls for proposals open to the Strasbourg scientific community

→ Scientific advisory board evaluating the project with regard to “risk – druggability” balance

Exploratory & consolidated grants

Dedicated task-force (open-lab): to support R&D programs

➤ **Inedis: To reinforce technology transfer efficacy and favour start-up/spin-off creation**



- Focused strategic actions at the hinge between the academy and the creation of start-ups
- Leverage and coordinate support from local actors (SEMIA, SATT Conectus, Biovalley France)
- Focused investment capabilities (local investors, Région Grand-Est, BPI, international investors)

Investment funds and consultancies



Institutions for technology transfer



➤ **Euridis: a graduate school interdisciplinary program to foster entrepreneurial spirit in Drug Discovery and Development.**

Launched in 2021

- Open to different Master's students
- Interface Chemistry / Biology / Drug Discovery / Legal / Technology
- Focus on Intellectual Property / Technology Transfer / Entrepreneurship
- **University Diploma: "Research and Therapeutic Innovation"**

I Introduction Classes (18h)
Biological / Chemical /
Legal toolboxes

II Drug Discovery & Development (24h)
Initiation to drug discovery and development
From a hit compound to a preclinical candidate
Interventions from professionals in pharmaceutical industry

III Innovation and transfer (12h)
Market, Transfer, Intellectual
property, Entrepreneurship

Interventions from entrepreneurship and IP experts

IV Case studies (16h)
Two thematic workshops: From an
unmet medical need to drug discovery

V Possibility for students to take
responsibility for a research project
very early in their cursus

Winners: Funding of PhD program
270 k€ = 2 PhD grants + starting
package

Pairs of students with different backgrounds
Accompanied by industrial and academic mentors

- Identify a medical need
- Address an interdisciplinary research topic
- Support this research project (jury: academia & industry)



Challenge **DDD**

Drug Discovery & Development



Lara El Kaakour

M2 Research in biomedicine

Dylan Mastrippolito

M2 Pharmacology and toxicology

Céline Berdous

M2 Right to health care in Europe

Novel therapeutic approach in NASH based on the combination of a pharmacological peptide and cell-based therapy